Suzuken Co (9987.T) Stock Price
Suzuken Co Price
Over the last 19 years Suzuken Co grew revenue by 2.9% annually, reaching 2.49 T JPY. Earnings per share have grown at 4.1% per year over the last 19 years. For Suzuken Co, the net margin of 1.5% is broadly stable versus 0.6% a few years ago. At today's price the dividend yield works out to roughly 2.59%. The payout ratio is around 12% of earnings. The dividend has grown at 6.8% per year over the past 19 years. The consensus 12-month price target for Suzuken Co is 6,436.20 JPY, about 122.3% above where the stock trades today. Of 8 analysts, 4 rate the stock a buy — an overall Buy consensus.
Suzuken Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Suzuken Co business model & stock analysis
Frequently asked questions about Suzuken Co
The business model of Suzuken Co Ltd revolves around the distribution and sales of pharmaceutical and medical products in Japan. As a leading company in the healthcare industry, Suzuken operates through various segments including Pharmaceutical Wholesale, Pharmacy Chain, Medical Instruments and Equipment, and Home Healthcare. Suzuken collaborates with manufacturers to procure and distribute a wide range of pharmaceutical products to hospitals, clinics, and pharmacies across Japan. The company aims to enhance healthcare accessibility by providing high-quality medical supplies and services to customers. Suzuken's comprehensive business model enables it to contribute effectively to the healthcare system and meet the evolving needs of the Japanese market.
Suzuken Co Ltd is primarily active in the pharmaceutical industry.
The main competitors of Suzuken Co Ltd in the market include McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health Inc. These companies are global pharmaceutical wholesale distributors that operate in a similar industry as Suzuken. McKesson Corporation, based in the United States, is one of the largest healthcare services and information technology companies. AmerisourceBergen Corporation, also based in the United States, is a leading provider of pharmaceutical distribution and related healthcare services. Cardinal Health Inc. is another prominent player in the healthcare services and products sector, with operations in over 60 countries.
Suzuken Co Ltd is a renowned Japanese company with a rich history and background. Established in 1921, Suzuken initially operated as a wholesale distributor for pharmaceutical products. Over the years, the company expanded its operations and diversified its portfolio. Today, Suzuken Co Ltd is a leading provider of comprehensive healthcare services, including pharmaceutical distribution, home healthcare, clinical diagnostics, and healthcare IT solutions. The company's commitment to innovation and customer-centric approach has propelled its growth and reputation in the industry. With a strong presence in Japan and expanding globally, Suzuken Co Ltd continues to play a crucial role in shaping the future of healthcare delivery.
Suzuken Co Ltd, a leading stock, has achieved several significant milestones over the years. One milestone is its successful expansion into the global market, establishing a strong presence in various countries. Suzuken has also demonstrated consistent growth through strategic partnerships and mergers, enhancing its product portfolio and market position. Moreover, the company has received recognition for its commitment to innovation and quality, earning prestigious industry awards. Suzuken's consistent financial performance and ability to adapt to evolving market trends further highlight its success as a trusted player in the stock industry. As a result, Suzuken Co Ltd continues to secure its position as a market leader, driving value and growth for its shareholders.
Suzuken Co Ltd is primarily present in Japan.
Suzuken Co Ltd represents values of trust, integrity, and innovation. The company's corporate philosophy is focused on contributing to society through its healthcare business. Suzuken Co Ltd strives to provide high-quality products and services that improve the well-being and health of individuals. With a strong commitment to ethical business practices, Suzuken Co Ltd continually seeks to meet the evolving needs of customers and stakeholders, fostering long-term partnerships built on reliability and excellence. Through its dedication to advancing healthcare solutions, Suzuken Co Ltd aims to create a healthier and more prosperous future for all.
Analysts currently set an average price target of 6,303.60 JPY for the Suzuken Co stock (median: 6,436.20 JPY), implying +111.3 % versus the latest price. The consensus is based on 8 analyst ratings.
8 analysts currently rate the Suzuken Co stock: 4 recommend buying, 4 holding and 0 selling.
Converted at the current exchange rate, the Suzuken Co share trades at 16.47 EUR (2,895.50 JPY).
The Suzuken Co share (9987.T) is listed on 3 stock exchanges, including: Tokio (JPX) (9987.T), Hongkong (HKEX) (9987.HK).
Suzuken Co Ltd is a Japanese company specializing in the sale and distribution of pharmaceuticals, medical devices, and diagnostic tests. The company was founded in 1934 and is headquartered in Kyoto, Japan. It operates in various segments, including pharmaceutical supply, medical device trading, diagnostic tests, and other business areas such as health and care products and the Suzuken Pharmacy chain. Suzuken has partnerships with international companies to meet the global demand for its products. It has made acquisitions and partnerships in recent years to expand its business activities and has focused on developing innovative services and technologies. Overall, Suzuken is a key player in the Japanese healthcare industry and is well-positioned to grow and expand its business in the future.
The revenue of Suzuken Co is 2.49 T JPY. This figure is based on current financial data and reflects the company's business performance.
The profit of Suzuken Co is 38.14 B JPY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Suzuken Co is currently 5.11. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Suzuken Co stock.
The price-to-sales ratio (P/S) of Suzuken Co is currently 0.08. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Suzuken Co stock.
The Eulerpool Quality Score for Suzuken Co is 2/10.
The ISIN of Suzuken Co is JP3398000004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Suzuken Co is 914027. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Suzuken Co is 9987.T. The ticker symbol is used to trade Suzuken Co shares on the stock exchange.
Suzuken Co stock
Suzuken Co Peer Group
Suzuken Co Ticker
Suzuken Co FIGI
All fundamentals and in-depth analysis of Suzuken Co
Our stock analysis for Suzuken Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Suzuken Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.